Canagliflozin and Cardiovascular disease- results of the CANVAS trial

Canagliflozin is a new novel oral antidiabetic agent belonging to the class of sodium–glucose co-transporter 2 (SGLT2) inhibitors, inhibiting glucose reabsorption in the proximal tubule, leading to increased urinary glucose excretion and subsequently to reduction in plasma glucose concentration, in...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Syed Raza, Najim, Najla Issa, Abbasi, Zainab, Fatima, Mazia, Jangda, Ayesha Altaf, Shahnawaz, Waqas, Shahid, Maira, Shah, Syed Arbab
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197007/
https://www.ncbi.nlm.nih.gov/pubmed/30357039
http://dx.doi.org/10.1080/20009666.2018.1521245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197007/
https://www.ncbi.nlm.nih.gov/pubmed/30357039
http://dx.doi.org/10.1080/20009666.2018.1521245

Ejemplares similares